ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO1446

Serum and Glomerular Complement Components as Biomarkers in the First South Asian Prospective Longitudinal Observational IgA Nephropathy Cohort (GRACE-IgANI)

Session Information

Category: Glomerular Diseases

  • 1202 Glomerular Diseases: Immunology and Inflammation

Authors

  • Alexander, Suceena, Christian Medical College Vellore, Vellore, Tamil Nadu, India
  • Varughese, Santosh, Christian Medical College Vellore, Vellore, Tamil Nadu, India
  • Thomas, Athul, Christian Medical College Vellore, Vellore, Tamil Nadu, India
  • Eapen, Jeethu Joseph, Christian Medical College Vellore, Vellore, Tamil Nadu, India
  • John, Elenjickal Elias, Christian Medical College Vellore, Vellore, Tamil Nadu, India
  • Valson, Anna T., Christian Medical College Vellore, Vellore, Tamil Nadu, India
  • David, Vinoi George, Christian Medical College Vellore, Vellore, Tamil Nadu, India
  • Feehally, John, University of Leicester, Leicester, Leicestershire, United Kingdom
  • Barratt, Jonathan, University of Leicester College of Life Sciences, Leicester, Leicester, United Kingdom
  • John, George, Christian Medical College Vellore, Vellore, Tamil Nadu, India
  • Seelen, Marc Maj, Universitair Medisch Centrum Groningen, Groningen, Groningen, Netherlands
  • Daha, Mohamed R., Universitair Medisch Centrum Groningen, Groningen, Groningen, Netherlands
Background

The Glomerular Research And Clinical Experiments- IgA Nephropathy in Indians is a prospective longitudinal cohort . The study protocol has been published and is registered with WHO trial id: ISRCTN36834159. The role of serum and glomerular complement components in South Asian IgAN is unknown.

Methods

201 consenting adult IgAN patients were consecutively recruited post kidney biopsy. 192 (97%) patients completed 3 years. Serum complement C3 and C4 levels and glomerular C3d, C4d and C5b-9 by IHC were quantified at baseline in IgAN patients. Composite outcome (CO) was defined as ≥50% fall in eGFR from baseline and/or eGFR <15ml/min/1.73m2 or RRT/death.

Results

195 patients (97%) completed 3 year longitudinal follow-up. Lower serum C3 was significantly associated with S1, T1/T2 according to the Oxford MEST grading and with global glomerulosclerosis (GS>33%) whereas higher C4 levels were associated S1 scores. Increased mesangial C3d deposition correlated with increased mean arterial pressure, proteinuria, decreased serum albumin, decreased eGFR and with GS>33%. Similar to C3d, increased mesangial C4d correlated with increased systolic blood pressure, decreased serum protein and decreased eGFR and with GS>33%. Mesangial deposition of C5b-9 did not have any clinical associations. Lower serum C3, higher serum C4 and incrased mesangial C3d was significantly associated with CO over three years.

Conclusion

Serum and tissue complements could be potential biomarkers for severity and progression n the GRACE-IgANI cohort. This requires furhter validation.

Associations with clinical variables

Funding

  • Government Support – Non-U.S.